A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

S. H. Bernstein, E. Epner, J. M. Unger, M. LeBlanc, E. Cebula, R. Burack, L. Rimsza, T. P. Miller, R. I. Fisher

Research output: Contribution to journalArticle

76 Scopus citations

Abstract

Background: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. Patients and methods: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). Results: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those ≤65 years) and the median overall survival (OS) was 6.8 years. Conclusions: Although this regimen is toxic, it is active for patients ≤65 years of age and can be given both at academic centers and in experienced community centers.

Original languageEnglish (US)
Pages (from-to)1587-1593
Number of pages7
JournalAnnals of Oncology
Volume24
Issue number6
DOIs
StatePublished - Jun 1 2013

Keywords

  • Dose-intensive
  • Mantle cell
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213'. Together they form a unique fingerprint.

  • Cite this